<DOC>
	<DOCNO>NCT01069211</DOCNO>
	<brief_summary>The purpose study assess clinical outcome Letrozole treatment accord estrogen receptor expression postmenopausal woman hormone receptor positive breast cancer .</brief_summary>
	<brief_title>Clinical Outcomes After Letrozole Treatment According Estrogen Receptor Expression Postmenopausal Women</brief_title>
	<detailed_description>This study aim evaluate follow : 1 . Validity Assessment : 1 . Primary End Point : To evaluate 5-year diseae free survival rate Letrozole treatment accord estrogen receptor expression postmenopausal woman 2 . Secondary End Point : To evaluate overall survival rate ( OS ) Time distance recurrence ( TTDR ) Hormonal therapy postmenopausal woman hormone receptor positive breast cancer 2 . Safety Assessment : To evaluate adverse event include serious adverse event Letrozole treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Patients estrogen receptor ( + ) and/or progesterone receptor ( + ) 2 . Postmenopausal state define follow condition , least one , b 1 . Serum FSH ≥ 30 mIU/mL Amenorrhea ≥ 1 year 55 year , 55 year 2 . Bilateral oophorectomy 3 . Patients undergone surgery breast cancer within 12 week terminate chemotherapy surgery within 4 week . 4. WHO ( ECOG ) performance status 02 5 . Adequate haematological function , renal function , hepatic function . 6 . No evidence metastasis . 1 . Metachronous bilateral breast cancer . 2 . Metastatic breast cancer ( stage IV ) 3 . Other hormone therapy Hormonal replacement therapy give within previous 4 week , except Estring , Vagifem , Estrogen Cream . 4 . Patients ChildPugh grade C , serum creatinine &gt; 2xUNL 5 . Patients gastrectomy , small bowel resection , malabsorption syndrome dysphagia .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Breast cancer , Letrozole</keyword>
	<keyword>postmenopause</keyword>
	<keyword>hormone receptor positive breast cancer</keyword>
</DOC>